The 3,600 sqft facility will help develop the MIMIX sustained-release intradermal microneedle patch, which is planned for proof-of-concept trials for COVID-19 in 2022
Are you an expert in cleanroom technology or contamination control? We are seeking dynamic speakers to share their insights on the latest developments and innovations in the...
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.